Oral nitrate supplementation to enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-controlled, randomised parallel group study.
Administration, Oral
Aged
Dietary Supplements
Dose-Response Relationship, Drug
Double-Blind Method
Exercise
/ physiology
Exercise Therapy
/ methods
Female
Follow-Up Studies
Humans
Male
Middle Aged
Nitrates
/ administration & dosage
Prospective Studies
Pulmonary Disease, Chronic Obstructive
/ physiopathology
Quality of Life
Treatment Outcome
COPD pharmacology
pulmonary rehabilitation
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
31
10
2019
revised:
23
03
2020
accepted:
15
04
2020
pubmed:
8
5
2020
medline:
20
8
2020
entrez:
8
5
2020
Statut:
ppublish
Résumé
Dietary nitrate supplementation has been proposed as a strategy to improve exercise performance, both in healthy individuals and in people with COPD. We aimed to assess whether it could enhance the effect of pulmonary rehabilitation (PR) in COPD. This double-blind, placebo-controlled, parallel group, randomised controlled study performed at four UK centres, enrolled adults with Global Initiative for Chronic Obstructive Lung Disease grade II-IV COPD and Medical Research Council dyspnoea score 3-5 or functional limitation to undertake a twice weekly 8-week PR programme. They were randomly assigned (1:1) to either 140 mL of nitrate-rich beetroot juice (BRJ) (12.9 mmol nitrate), or placebo nitrate-deplete BRJ, consumed 3 hours prior to undertaking each PR session. Allocation used computer-generated block randomisation. The primary outcome was change in incremental shuttle walk test (ISWT) distance. Secondary outcomes included quality of life, physical activity level, endothelial function via flow-mediated dilatation, fat-free mass index and blood pressure parameters. 165 participants were recruited, 78 randomised to nitrate-rich BRJ and 87 randomised to placebo. Exercise capacity increased more with active treatment (n=57) than placebo (n=65); median (IQR) change in ISWT distance +60 m (10, 85) vs +30 m (0, 70), estimated treatment effect 30 m (95% CI 10 to 40); p=0.027. Active treatment also impacted on systolic blood pressure: treatment group -5.0 mm Hg (-5.0, -3.0) versus control +6.0 mm Hg (-1.0, 15.5), estimated treatment effect -7 mm Hg (95% CI 7 to -20) (p<0.0005). No significant serious adverse events or side effects were reported. Dietary nitrate supplementation appears to be a well-tolerated and effective strategy to augment the benefits of PR in COPD. ISRCTN27860457.
Identifiants
pubmed: 32376732
pii: thoraxjnl-2019-214278
doi: 10.1136/thoraxjnl-2019-214278
doi:
Substances chimiques
Nitrates
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
547-555Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.